Exelixis (Alameda, CA). 2024 revenue ~$2.1B. Cabometyx (cabozantinib) for renal cell and hepatocellular carcinoma. Cometriq. Small molecule kinase inhibitor platform. Ibruance partnership with Pfizer.
12:54:07 AM · Jul 9, 2026
Sign in to reply and join the conversation.